Abstracts tagged "remission and rheumatoid arthritis (RA)"

Abstract Number: 1340 • 2012 ACR/ARHP Annual Meeting
Effects of Subcutaneous Abatacept or Adalimumab On Remission and Associated Changes in Physical Function and Radiographic Outcomes: One Year Results From the Ample (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate) Trial
Roy Fleischmann¹, Michael H. Schiff², Michael E. Weinblatt³, Michael A. Maldonado⁴, Elena M. Massarotti⁵ and Yusuf Yazici⁶, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Rheumatology Division, University of Colorado, Denver, CO, ³Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁴Medical Strategy, Bristol-Myers Squibb, Princeton, NJ, ⁵Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶New York University, New York, NY
Background/Purpose: Advancements in the understanding of Rheumatoid Arthritis (RA) have led to the development of novel therapeutics and treatment guidelines that target remission as an…
Abstract Number: 1328 • 2012 ACR/ARHP Annual Meeting
The Higher and Faster Increasing Schedule of Methotrexate May Not Be the Best: The Accumulation of Intracellular Longer Chain Methotrexate Polyglutamates Was Facilitated by the Extra-Low-Dose Methotrexate Treatment
Yoshinobu Koyama¹, Kazunori Hase², Daisuke Hidaka², Shuji Nagano³, Toshiyuki Ota³ and Ayumi Uchino², ¹Division of Rheumatology, Okayama Red Cross General Hospital, Okayama, Japan, ²Iizuka Hospital, Iizuka, Japan, ³Center for Rheumatic Diseases, Iizuka Hospital, Iizuka, Japan
Background/Purpose: Although data are conflicting with regard to the clinical utility of MTX polyglutamates (PGs) measurements as a predictor of the efficacy or toxicity in…
Abstract Number: 1301 • 2012 ACR/ARHP Annual Meeting
Predictors of Significant Disease Activity Score-28 (Using C-reactive protein) Remission Achieved with Intravenous Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Trial
Clifton O. Bingham III¹, Michael Weinblatt², Alan Mendelsohn³, Lilianne Kim⁴, Michael Mack⁵, Jiandong Lu⁵, Daniel Baker³ and Rene Westhovens⁶, ¹Department of Medicine, Johns Hopkins University, Baltimore, MD, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁶Rheumatology, University Hospital KU Leuven, Leuven, Belgium
Predictors of Significant Disease Activity Score-28 (Using C-reactive protein) Remission Achieved with Intravenous Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of…
Abstract Number: 481 • 2012 ACR/ARHP Annual Meeting
Duration of Sustained Remission and Differences in Responce Between Medications, in Tumor Necrosis factor inhibitor Treated Rheumatoid Arthritis Patients
Jon T. Einarsson¹, Pierre Geborek², Tore Saxne³ and Meliha C. Kapetanovic⁴, ¹Dept of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ²Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, ³Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Section of Rheumatology, Dept of Clinical Sciences Lund, Lund, Sweden
Background/Purpose: Remission is increasingly becoming a treatment goal in rheumatoid arthritis (RA) patients and DAS28 remission criteria are widely used, despite their limitations. The purpose…
Abstract Number: 390 • 2012 ACR/ARHP Annual Meeting
Performance of Criteria for Remission in a Long-Term Observational Study of Patients with Early Rheumatoid Arthritis
Bjorn Svensson¹, Maria LE Andersson², Sidona-Valentina Bala³, Kristina Forslind⁴ and Ingiäld Hafström⁵, ¹Section of Rheumatology, Institution of Clinical Science, Lund University, Lund, Sweden, ²R&D Center, Spenshult Hospital, Oskarström, Sweden, ³Department of Health Sciences,, Lund University, Lund, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁵Unit of Rheumatology, Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Remission is widely accepted as the goal of treatment in RA and has to be sustained to keep joint damage at a minimum (Smolen…
Abstract Number: 392 • 2012 ACR/ARHP Annual Meeting
Analysis of Factors Impact On Patient Global Assessment in Daily Practice Based On Observational Cohort IORRA (Institute of Rheumatology, Rheumatoid Arthritis)
Yasushi Inoue¹, Eiichi Tanaka², Ayako Nakajima³, Eisuke Inoue⁴, Akiko Kobayashi⁴, Daisuke Hoshi¹, Naoki Sugimoto⁴, Kumi Shidara⁴, Yohei Seto⁴, Atsuo Taniguchi⁴, Shigeki Momohara¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient global assessment (PtGA) is an element of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). This definition has been reported to better…
Abstract Number: 2661 • 2012 ACR/ARHP Annual Meeting
Disease Activity Score 28-Joint Count: Are Erythrocyte Sedimentation Rate and C-Reactive Protein Versions Comparable?
Roy Fleischmann¹, Désirée van der Heijde², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴, Lisa Marshall⁵ and Eustratios Bananis⁴, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., Collegeville, PA
Background/Purpose: Frequently DAS28-CRP is utilized instead of DAS28-ESR to assess rheumatoid arthritis (RA) disease activity; however, values for remission and low disease activity (LDA) for…
Abstract Number: 394 • 2012 ACR/ARHP Annual Meeting
Remission After One Year in ACPA Positive and ACPA Negative Patients with Early Arthritis
K.V.C. Wevers-de Boer¹, L. Heimans¹, K. Visser¹, A.A. Schouffoer², T.H.E. Molenaar³, J.B. Harbers⁴, C. Bijkerk⁵, I. Speyer⁶, M. de Buck⁷, P.B. de Sonnaville⁸, B.A. Grillet⁹, Tom Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Haga Hospital, The Hague, Netherlands, ³Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Franciscus Hospital, Roosendaal, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Bronovo Hospital, Den Haag, Netherlands, ⁷MCH, The Hague, ⁸Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, ⁹Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: To evaluate possible differences in clinical response after one year of remission steered treatment in Anti Citrullinated Protein Antibody (ACPA) positive and negative RA…
Abstract Number: 2639 • 2012 ACR/ARHP Annual Meeting
Residual Disease Activity in Patients with Early Rheumatoid Arthritis Who Were Classified As Being in Remission According to 8 Different Descriptions: Post Hoc Analysis of the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Francis Guillemin⁴, Bruno Fautrel⁵ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France
Background/Purpose: No single gold standard for remission is available for rheumatoid arthritis (RA). All available descriptions, including 2 proposed by an ACR/EULAR committee, allow residual…
Abstract Number: 396 • 2012 ACR/ARHP Annual Meeting
Prevalence, Concordance and Predictors of Early and Sustained Remission Assessed by Various Indices in the French Early Arthritis Espoir Cohort
Cédric Lukas¹, Ihsane Hmamouchi², Xavier Le Loet³, Bruno Fautrel⁴ and Bernard Combe⁵, ¹Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ²El Ayachi Hospital, Rabat, Morocco, ³Rheumatology Department, CHU de ROUEN, Rouen, France, ⁴Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁵Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Clinical remission is the best achievable state in patients with rheumatoid arthritis (RA). The definition of remission, however, is still under debate. The aim…
Abstract Number: 2606 • 2012 ACR/ARHP Annual Meeting
Patient Reported Outcomes in Early Arthritis Patients
L. Heimans¹, K.V.C. Wevers-de Boer¹, K. Visser¹, R. Goekoop², T.H.E. Molenaar³, B.A. Grillet⁴, Tom Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Haga Hospital, The Hague, Netherlands, ³Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: To investigate patient reported outcomes (PROs) of functioning and health related quality of life (HRQOL) after 1 year remission (DAS
Abstract Number: 399 • 2012 ACR/ARHP Annual Meeting
Can Sustained Remission of Rheumatoid Arthritis Be Predicted? an Analysis From the Japanese National Database of Rheumatic Disease (NinJa)
Yoichiro Haji¹, Mitsumasa Kishimoto¹, Ryo Rokutanda¹, Sachiko Ohde², Gautam A. Deshpande³, Yuri Ohara¹, Chisun Min¹, Yasuhiro Suyama¹, Hisanori Shimizu¹, Ken-ichi Yamaguchi¹, Akira Takeda⁴, Yukio Matsui¹, Masato Okada¹ and Shigeto Tohma⁵, ¹Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Center for Clinical Epidemiology, St.Luke's Life of Science Institute, Tokyo, Japan, ³Center for Clinical Epidemiology, St. Luke's Life Science Instutute, Tokyo, Japan, ⁴Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan, ⁵Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
Background/Purpose: Achievement of clinical remission in rheumatoid arthritis (RA) is now the goal of therapy to reduce joint damage and disability, and maintain or improve…
Abstract Number: 2608 • 2012 ACR/ARHP Annual Meeting
Time in Remission Is Important for Improvement of Physical Function in Patients with Rheumatoid Arthritis (RA)
Helga Radner¹, Farideh Alasti², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Physical function is one of the major outcomes in RA as it predicts work disability, quality of life, health care resource utilisation and mortality.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].